På grund af muligheden for alvorlige bivirkninger hos det diende barn, skal det besluttes, om enten amningen eller behandlingen skal ophøre.
Because of the potential for serious adverse reactions in nursing infants a decision should be made whether to discontinue breast- feeding or Extavia therapy.